readthroughSign in
Nov 12, 2026Trial update

Innovent registers Phase II trial of IBI3011 for acute gouty arthritis

The company listed a 132-participant study testing its IL-RAP antibody against an active comparator in patients with acute gout flares.

Innovent Biologics' clinical trial record for IBI3011 in acute gouty arthritis shows a status update as of 2026-11-12.

  • IBI3011, described as a recombinant Anti-IL-RAP humanized monoclonal antibody injection1, is being tested in a Phase II study for subjects with acute gout flare. The trial is recruiting, with an actual start date of 2026-10-29 and estimated primary completion on 2027-05-111. The study plans to enroll 132 participants1 and compares subcutaneous IBI3011 against an active comparator arm. The primary outcome measures the change in gout pain intensity in the target joint using a Visual Analog Scale, where patients score pain from no pain to unbearable pain at 72 hours post-dose1. Eligible participants must meet the 2015 American College of Rheumatology (ACR) Gout Classification Criteria1 and have a history of at least 2 gouty arthritis flares within 1 year prior to study drug administration1.

Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.